Similarly, women with the XRCC1-399 Gln/Gln genotype presented with a significantly increased risk for grade II and grade III tumours (OR 1.80, 95% CI 1.06–3.07) when compared to those with the Arg/Arg genotype, while no increase was seen for grade I tumours (OR 1.10, 95% CI 0.75–1.62). Here, XRCC1 is linked to neoplasm.